- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01536106
Rapid Delivery of Autologous Bone Marrow Derived Stem Cells in Acute Myocardial Infarction Patients. (AMIRST)
Intracoronary Infusion of Concentrated Autologous Bone Marrow Mononuclear Cells in Acute Myocardial Infarction Patients Utilizing a Novel Point-of-Care Device for Rapid-Delivery of Stem Cells (AMIRST)
The primary objective of the study is to determine the feasibility and safety of intracoronary administration of autologous bone marrow derived mononuclear cell product in patients at risk for clinically significant cardiac dysfunction following AMI.
The secondary objective of the study is to assess the effect on cardiac function and infarct region perfusion. A concurrent placebo control patient group meeting eligibility but not receiving autologous bone marrow derived stem cells will be evaluated similar to the treated group to assess the rate of significant spontaneous improvement in cardiac function.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Emerging evidence indicate that progenitor stem cells derived from bone marrow can be used to improve cardiac function in acute myocardial infarction patients. There is a great potential for stem cell therapy, using a variety of cell precursors to contribute to new blood vessel formation and muscle preservation in the myocardial infarct zone. The administration of cells via an infusion through the infarct related artery appears to be feasible and result in a clinical effect in some studies. Across the globe AMI is the leading cause of morbidity and mortality. This cannot be prevented by optimal standard therapies i.e. balloon or stent dilation of the infarct vessels.
The study is a double blind, placebo controlled, randomized, multicenter trial. Male or female patients between 18-75 years with first incidence of Acute Myocardial Infarction(AMI) and LVEF less than or equal to 40% are included in the study. Patients who have undergone successful percutaneous intervention (PCI) within ≤ 24 hours after onset of symptoms (PTCA/stent) or / and Thrombolysed patients having TIMI-3 flow are eligible to take part in the study.
A total of 30 subjects will be recruited and randomly assigned to receive concentrated BMMNC or placebo. All patients will undergo bone marrow aspiration within 3-10 days from the index event(infarction). Bone Marrow(BM) will be processed utilizing point of care technology. Following cell processing, the concentrated BMMNC or placebo control is infused directly into the infarct related artery using the stop flow method. Clinical follow up for all the subjects at 1,30, 60, 90, 180 and 360 days will be performed from the day of the procedure, with primary and secondary end points evaluated for both study arms.
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: Kenneth Harris, MS
- Número de telefone: 13234207766
- E-mail: ken.harris@totipotentrx.com
Estude backup de contato
- Nome: Venkatesh Ponemone, PhD
- Número de telefone: 911244976860
- E-mail: ponemone@totipotentrx.com
Locais de estudo
-
-
-
Hyderabad, Índia, 500034
- CARE Hospitals, Banjara Hills
-
Contato:
- Sreenivas A Kumar
- Número de telefone: 040-30418126
- E-mail: arramraj@yahoo.com
-
Investigador principal:
- Sreenivas A Kumar, MD, DM, FACC
-
Subinvestigador:
- Venkatesh Ponemone, PhD
-
New Delhi, Índia, 110025
- Fortis Escorts Heart Institute and Research Centre
-
Subinvestigador:
- Venkatesh Ponemone, PhD
-
Contato:
- Ashok Seth, FRCS, FSCAI
- Número de telefone: 911147134232
- E-mail: ashok.seth@fortishealthcare.com
-
Contato:
- Vinay Sanghi, MD
- Número de telefone: 911147135000
- E-mail: vinay.sanghi@fortishealthcare.com
-
Investigador principal:
- Ashok Seth, FRCS, FSCAI
-
Subinvestigador:
- Upendra Kaul, MD, DM, FACC
-
Subinvestigador:
- Vishal Rastogi, MD, DM
-
Subinvestigador:
- Vinay Sanghi, FACP,FACC
-
Subinvestigador:
- Mona Bhatia, MD
-
New Delhi, Índia, 110070
- Fortis Flt. Lt. Rajan Dhall Hospital
-
Subinvestigador:
- Venkatesh Ponemone, PhD
-
Subinvestigador:
- Mona Bhatia, MD
-
Contato:
- Upendra Kaul, MD
- Número de telefone: 911147135000
- E-mail: upendra.kaul@fortishealthcare.com
-
Contato:
- Tapan Ghose, MD
- Número de telefone: 911147134232
- E-mail: tapan.ghose@fortishealthcare.com
-
Investigador principal:
- Upendra Kaul, MD, DM, FACC
-
Subinvestigador:
- Tapan Ghose, MD
-
Subinvestigador:
- Ripen Gupta, MD
-
Subinvestigador:
- Ranjan Kachru, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Male or Female of age 18 - 75 years
- Incidence of first myocardial infarction
- Acute STEMI with LV hypokinesia involving anteroseptal, lateral or inferior walls
- LVEF < 40% pre-intervention
- Successful percutaneous intervention (PCI) within ≤ 24 hours after onset of symptoms (PTCA/stent) or / and Thrombolysed patients having TIMI-3 flow.
- Written informed consent
Exclusion Criteria:
- Multi-vessel coronary disease requiring surgical intervention (CABG) or left main coronary artery disease > 50% blockage
- Previous history of CABG
- Pulmonary edema
- Cardiogenic shock
- Myocarditis
- Renal or hepatic dysfunction
- Hematologic disease
General Exclusion Criteria:
- Alcohol or drug dependency, active or uncontrolled acute myocarditis
- HIV, HBV, or HCV infections
- Evidence of malignant or hematological diseases
- Metal implants of any kind
- Claustrophobia
- Renal insufficiency
- History of bleeding disorder
- Anemia (haemoglobin <8.5mg/dl)
- Platelet count <100,000/ml
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Treatment
Implantation of bone marrow derived mononuclear cells
|
Intracoronary administration of concentrated BMMNC on the same day of BM aspiration using point of care technology.
Outros nomes:
|
Comparador de Placebo: Placebo Control
Infusion of autologous peripheral blood
|
Intracoronary infusion of autologous peripheral blood.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Number of adverse events as a measure of safety
Prazo: 12 Months
|
Feasibility and safety of Intracoronary infusion of autologous BMMNCs processed through intraoperative point of care technology, freedom from arrhythmia's.
|
12 Months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Changes in the global Left Ventricular Ejection Fraction(LVEF), LV volumes-End Systolic Volume (ESV) and End Diastolic Volume (EDV), infarct size, myocardial mass, myocardial viability and regional wall motion abnormalities.
Prazo: 12 Months
|
Changes in the global Left Ventricular Ejection Fraction(LVEF), LV volumes-End Systolic Volume (ESV) and End Diastolic Volume (EDV), infarct size, myocardial mass, myocardial viability and regional wall motion abnormalities measured by Cardiac MRI and assessed by central Core lab.
|
12 Months
|
Major adverse cardiac events (MACE)
Prazo: 12 Months
|
MACE was defined as the composites of any cause of death, myocardial infarction, revascularization of the target vessel, re-hospitalization for heart failure, and life-threatening arrhythmia.
|
12 Months
|
Quality of life
Prazo: 12 Months
|
Quality of life assessment is done using short-form 36, Minnesota living with heart failure questionnaire and Seattle Angina Questionnaire
|
12 Months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Diretor de estudo: Venkatesh Ponemone, PhD, TotipotentRX Cell Therapy Pvt. Ltd.
- Cadeira de estudo: Kenneth Harris, MS, TotipotentRX Cell Therapy Pvt. Ltd.
- Investigador principal: Ashok Seth, FRCP, FACC, Fortis Escorts Heart Institute and Research Centre
- Investigador principal: Upendra Kaul, MD,DM, FACC, Fortis Flt. Lt. Rajan Dhall Hospital
- Investigador principal: Sreenivas A Kumar, MD, DM, FACC, CARE Hospitals, Hyderabad, India
Publicações e links úteis
Publicações Gerais
- Roncalli J, Mouquet F, Piot C, Trochu JN, Le Corvoisier P, Neuder Y, Le Tourneau T, Agostini D, Gaxotte V, Sportouch C, Galinier M, Crochet D, Teiger E, Richard MJ, Polge AS, Beregi JP, Manrique A, Carrie D, Susen S, Klein B, Parini A, Lamirault G, Croisille P, Rouard H, Bourin P, Nguyen JM, Delasalle B, Vanzetto G, Van Belle E, Lemarchand P. Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial. Eur Heart J. 2011 Jul;32(14):1748-57. doi: 10.1093/eurheartj/ehq455. Epub 2010 Dec 2.
- Strauer BE, Yousef M, Schannwell CM. The acute and long-term effects of intracoronary Stem cell Transplantation in 191 patients with chronic heARt failure: the STAR-heart study. Eur J Heart Fail. 2010 Jul;12(7):721-9. doi: 10.1093/eurjhf/hfq095. Erratum In: Eur J Heart Fail. 2013 Mar;15(3):360.
- Dohmann HF, Silva SA, Sousa AL, Braga AM, Branco RV, Haddad AF, Oliveira MA, Moreira RC, Tuche FA, Peixoto CM, Tura BR, Borojevic R, Ribeiro JP, Nicolau JC, Nobrega AC, Carvalho AC. Multicenter double blind trial of autologous bone marrow mononuclear cell transplantation through intracoronary injection post acute myocardium infarction - MiHeart/AMI study. Trials. 2008 Jul 3;9:41. doi: 10.1186/1745-6215-9-41.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- TPRX/POC/BMSC/AMIRST/1.0
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Autologous Bone marrow mononuclear cells
-
University Hospital, Basel, SwitzerlandConcluídoBiópsia de Medula ÓsseaSuíça